These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 7238644)

  • 1. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
    Eernisse JG; Brand A
    Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.
    Claas FH; Smeenk RJ; Schmidt R; van Steenbrugge GJ; Eernisse JG
    Exp Hematol; 1981 Jan; 9(1):84-9. PubMed ID: 7238645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of leukocyte-depleted platelet concentrates for prevention of HLA-alloimmunization in patients with frequent platelet transfusions: a prospective multi-institutional study using a polyester platelet filter].
    Handa M; Ikeda Y; Kurata Y; Tsubaki K; Horiuchi A; Furihata K; Kimura Y; Toyama K; Takamoto S; Tsukimoto I
    Rinsho Ketsueki; 1992 Apr; 33(4):451-60. PubMed ID: 1602608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.
    Andreu G; Dewailly J; Leberre C; Quarre MC; Bidet ML; Tardivel R; Devers L; Lam Y; Soreau E; Boccaccio C
    Blood; 1988 Sep; 72(3):964-9. PubMed ID: 3416079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukopoor platelet concentrates: a direct comparison of three blood filters.
    Medeiros LJ; Dzik WH
    Ann Clin Lab Sci; 1985; 15(3):237-40. PubMed ID: 3994293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-leukocyte and anti-platelet immunization and transfusions during aplastic anemias].
    Dausset J; Benbunan M
    Nouv Rev Fr Hematol (1978); 1976 Jun; 16(1):132-43. PubMed ID: 781619
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experience of HLA-matched platelet transfusion in patients who are refractory to random donor platelets].
    Sekiguchi S; Mitani T; Ohnuma M; Katoh T; Ikeda H; Nakase T; Morioka M; Sakurada K; Miyazaki T
    Hokkaido Igaku Zasshi; 1988 Jul; 63(4):552-61. PubMed ID: 3220437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases.
    Klingemann HG; Self S; Banaji M; Deeg HJ; Doney K; Slichter SJ; Thomas ED; Storb R
    Br J Haematol; 1987 May; 66(1):115-21. PubMed ID: 3593647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of HLA antibody formation in patients with hemato-oncologic diseases by using leukocyte depleted blood preparations].
    Adamzik ID; Jin J; Sachs V; Thomsen H
    Infusionsther Transfusionsmed; 1995 Feb; 22(1):9-13. PubMed ID: 7727966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
    Benson K; Fields K; Hiemenz J; Zorsky P; Ballester O; Perkins J; Elfenbein G
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):102-9. PubMed ID: 8211211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone marrow transplantation in aplastic anemia with refractory states in platelet transfusions].
    Kodoh H; Horiuchi N; Nakada H; Kumakawa J; Shirafuji N
    Rinsho Ketsueki; 1986 Jul; 27(7):1278-81. PubMed ID: 3537368
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
    Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
    Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thrombocyte replacement in hematologic diseases].
    Höcker P
    Wien Klin Wochenschr; 1985 Nov; 97(22):841-7. PubMed ID: 3909651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
    Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation.
    Snyder EL
    Yale J Biol Med; 1990; 63(5):419-27. PubMed ID: 2293501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.